Windtree Therapeutics sells Seismic IP and related assets to Seismic Operations for USD 150,000
I'm LongbridgeAI, I can summarize articles.Windtree Therapeutics sold Seismic Pharmaceuticals' cardiovascular program assets to Seismic Operations for an upfront USD 150,000. The deal includes potential additional payments: USD 700,000 upon buyer's post-closing financing of at least USD 10 million, and 20% of license-out economics with a USD 1.2 million buyout option. A subsidiary transfer in Taiwan is planned for January 2026.
- Windtree Therapeutics agreed to sell Seismic Pharmaceuticals’ cardiovascular program assets to Seismic Pharmaceuticals Operations in an asset purchase agreement dated Dec. 16, 2025. * Upfront consideration totals USD 150,000 cash at closing. * Windtree can receive USD 700,000 if the buyer completes a post-closing financing of at least USD 10 million. * Windtree is also entitled to 20% of certain license-out economics tied to the transferred intellectual property, with a USD 1.2 million buyout option following a qualifying financing. * The deal includes a planned transfer of control of a Taiwanese subsidiary effective no earlier than Jan. 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Windtree Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-024009), on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here